Accessory mutations maintain stability in drug-resistant HIV-1 protease

Journal of Molecular Biology

Volumn 410, Issue 4, 2011, Pages 756-760

  Chang, Max W ^a   Torbett, Bruce E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Differential scanning calorimetry; Drug resistance; HIV protease; Protein stability; Viral evolution

Indexed keywords

PROTEINASE;

ARTICLE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN STABILITY; VIRUS ISOLATION; VIRUS RESISTANCE; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80051749007     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.03.038     Document Type: Article

References (23)

1. Shafer, R. W. & Schapiro, J. M. (2008). HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10, 67-84
2. Kutilek, V. D., Sheeter, D. A., Elder, J. H. & Torbett, B. E. (2003). Is resistance futile? Curr. Drug Targets. Infect. Disord. 3, 295-309. (Pubitemid 38016619)
3. Schock, H. B., Garsky, V. M. & Kuo, L. C. (1996). Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J. Biol. Chem. 271, 31957-31963. (Pubitemid 26422220)
4. Liu, F., Boross, P. I., Wang, Y. F., Tozser, J., Louis, J. M., Harrison, R. W. & Weber, I. T. (2005). Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J. Mol. Biol. 354, 789-800. (Pubitemid 41735502)
5. Kozisek, M., Bray, J., Rezacova, P., Saskova, K., Brynda, J., Pokorna, J. et al. (2007). Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants. J. Mol. Biol. 374, 1005-1016. (Pubitemid 350052096)
6. Yanchunas, J., Jr., Langley, D. R., Tao, L., Rose, R. E., Friborg, J., Colonno, R. J. & Doyle, M. L. (2005). Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob. Agents Chemother. 49, 3825-3832. (Pubitemid 41233038)
7. Wang, X., Minasov, G. & Shoichet, B. K. (2002). Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320, 85-95. (Pubitemid 34722236)
8. Bloom, J. D., Gong, L. I. & Baltimore, D. (2010). Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science, 328, 1272-1275.
9. Bloom, J. D. & Arnold, F. H. (2009). In the light of directed evolution: pathways of adaptive protein evolution. Proc. Natl Acad. Sci. USA, 106, 9995-10000.
10. Fasan, R., Meharenna, Y. T., Snow, C. D., Poulos, T. L. & Arnold, F. H. (2008). Evolutionary history of a specialized p450 propane monooxygenase. J. Mol. Biol. 383, 1069-1080.
11. Peisajovich, S. G. & Tawfik, D. S. (2007). Protein engineers turned evolutionists. Nat. Methods,4, 991-994. (Pubitemid 350201764)
12. Todd, M. J., Luque, I., Velazquez-Campoy, A. & Freire, E. (2000). Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry, 39, 11876-11883.
13. Muzammil, S., Ross, P. & Freire, E. (2003). A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry, 42, 631-638. (Pubitemid 36133287)
14. Clavel, F. & Hance, A. J. (2004). HIV drug resistance. N. Engl. J. Med. 350, 1023-1035. (Pubitemid 38269279)
15. Heaslet, H., Lin, Y. C., Tam, K., Torbett, B. E., Elder, J. H. & Stout, C. D. (2007). Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Retrovirology, 4, 1.
16. Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J. et al. (1999). Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during sub-optimal therapy. AIDS, 13, 2349-2359.
17. Rhee, S. Y., Gonzales, M. J., Kantor, R., Betts, B. J., Ravela, J. & Shafer, R. W. (2003). Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31, 298-303. (Pubitemid 36150389)
18. Rhee, S. Y., Liu, T. F., Holmes, S. P. & Shafer, R. W. (2007). HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput. Biol. 3, e87.
19. Mahalingam, B., Wang, Y. F., Boross, P. I., Tozser, J., Louis, J. M., Harrison, R. W. & Weber, I. T. (2004). Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur. J. Biochem. 271, 1516-1524. (Pubitemid 38553557)
20. Xie, D., Gulnik, S., Gustchina, E., Yu, B., Shao, W., Qoronfleh, W. et al. (1999). Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH. Protein Sci. 8, 1702-1707. (Pubitemid 29379953)
21. Kuiken, C., Leitner, T., Apetrei, C., Hahn, B. & Mizrachi, I. (Eds.). (2010). HIV Sequence Compendium 2010. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico.
22. Bandaranayake, R. M., Kolli, M., King, N. M., Nalivaika, E. A., Heroux, A., Kakizawa, J. et al. (2010). The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways. J. Virol. 84, 9995-10003.
23. Perryman, A. L., Zhang, Q., Soutter, H. H., Rosenfeld, R., McRee, D. E., Olson, A. J. et al. (2010). Fragment-based screen against HIV protease. Chem. Biol. Drug Des. 75, 257-268.